Group 1 - Hubei Yihua has received acceptance from the Shenzhen Stock Exchange for its application to issue convertible bonds to unspecified objects [1] - Tongye Technology plans to acquire 91.69% of Beijing Silingke Semiconductor Technology Co., Ltd. for a total price of 561 million yuan [2] - Heng Rui Medicine has signed an exclusive licensing agreement with Hansoh Pharmaceutical, which includes a payment of 30 million yuan and potential milestone payments up to 190 million yuan [3] Group 2 - Jun Da Co. announced that its strategic cooperation framework agreement with Shangyi Optoelectronics will not significantly impact its current operating performance [4] - Jinchuan Group's wholly-owned subsidiary is jointly investing in a venture capital partnership to invest in Shanghai Gesi Information Technology Co., Ltd. [5] - Baili Tianheng plans to apply for the registration of debt financing tools not exceeding 10 billion yuan [6] Group 3 - Yuanda Environmental Protection announced the resignation of its chairman Chen Bin due to work changes [7] - Aerospace Development reported that its subsidiary's revenue accounted for less than 1% of the total revenue in the first three quarters of 2025 [8] - ST Huluwawa and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission for information disclosure violations [10] Group 4 - Jia Mei Packaging confirmed that it has no plans for significant changes to its main business or for a reverse merger in the next 36 months [11] - Wangfujing has won the bid for the duty-free project at Beijing Capital International Airport, with a guaranteed operating fee of 113 million yuan for the first year [12] - Siwei Liekong has suspended trading due to potential changes in control [13] Group 5 - Zhongchao Holdings announced a tax payment and late fee totaling 8.2881 million yuan [14] - Yongshuntai plans to conduct foreign exchange derivative trading with a total amount not exceeding 1.7 billion yuan in 2026 [15] - Guojin Securities has been approved to publicly issue company bonds not exceeding 25 billion yuan [16] Group 6 - Jincheng Pharmaceutical's subsidiaries are required to pay a total of 21.5968 million yuan in taxes and late fees [17] - China Shenhua's subsidiary has successfully completed the trial operation of its power generation unit [19] - Yijing Optoelectronics has received a hearing notice regarding the inability to advance its photovoltaic project [20] Group 7 - Jiga Development has received debt waivers totaling 378 million yuan from its controlling shareholder and related parties [21] - ST Lutong plans to apply to the Shenzhen Stock Exchange to revoke other risk warnings after a shareholder repaid funds [22] - Xin'ao Co. is progressing with the privatization of Xin'ao Energy and has completed significant asset restructuring foreign exchange registration [23]

Group 1 - ST HuLuWa and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The company claims that its production and operational activities are currently normal and orderly [1] Group 2 - BaiLi TianHeng plans to apply for the registration and issuance of debt financing instruments to optimize its debt structure, with a proposed issuance scale not exceeding 10 billion RMB [2] - The company asserts that this initiative will promote high-quality, stable, and sustainable development, benefiting all shareholders without harming minority shareholders [2] Group 3 - PaiLin Bio's controlling shareholder has signed a supplementary agreement for share transfer, extending the final deadline for the transaction to June 30, 2026, due to ongoing state-owned enterprise and antitrust reviews [3] - The share transfer is subject to compliance confirmation from the Shenzhen Stock Exchange and other regulatory approvals [3] Group 4 - JinCheng Pharmaceutical's subsidiary is required to pay approximately 21.6 million RMB in back taxes and penalties for the years 2017 and 2018, which have now been settled [4] - The company plans to seek compensation from previous equity transfer parties, with a potential impact of approximately -9.93 million RMB on the net profit attributable to shareholders for the current period [4] Group 5 - HengRui Pharmaceutical has signed an exclusive licensing agreement with HanSen Pharmaceutical for the SHR6508 project, allowing HanSen to commercialize the product [5] - This agreement enables HengRui to focus resources on priority treatment areas and leverage commercial services to expedite market entry [5]

Market News - The Ministry of Finance announced that a more proactive fiscal policy will continue in 2026, focusing on expanding fiscal expenditure, optimizing government bond tools, enhancing transfer payment efficiency, and improving expenditure structure [3] - The National Bureau of Statistics will release the December PMI data on December 31, with November's manufacturing PMI at 49.2%, a slight increase of 0.2 percentage points from October [4] - The People's Bank of China aims to significantly increase the scale and proportion of various long-term funds invested in A-shares, promoting a virtuous cycle between capital market stability and high-quality economic development [6] - The Shanghai and Shenzhen Stock Exchanges announced a series of fee reduction measures for 2026, expected to save over 1.9 billion yuan in total [7] Sector Developments - The Ministry of Industry and Information Technology established a standardization committee for humanoid robots and embodied intelligence, focusing on key technologies and industry standards [11] - The 2025 Shenzhen Brain Conference aims to create a platform for industry integration and innovation [13] - The 2025 China Green Hydrogen Industry Conference will discuss policies and technological breakthroughs that will impact the green hydrogen industry chain [14] Individual Stock Events - CATL plans to apply sodium batteries on a large scale in various sectors including battery swapping and energy storage in 2026 [17] - Xiaomi's co-founder plans to reduce holdings of up to $2 billion in B-class common stock [17] - ST Huluwawa and its chairman are under investigation for information disclosure violations [17] Lock-up Expiration - A total of 34 companies will have lock-up shares released this week, amounting to 3.697 billion shares with a total market value of approximately 58.895 billion yuan [18] - The peak lock-up expiration date is December 30, with 13 companies releasing shares worth a total of 27.645 billion yuan [18] Institutional Outlook - CITIC Securities highlights that 39 out of 360 industry/theme ETFs reached new highs in December, with a focus on communication and resource-related ETFs [25] - Guojin Securities identifies new investment themes emerging in 2026, emphasizing the importance of AI investments and the recovery of global manufacturing [26] - Zhongtai Securities believes there is still upward potential in the market before the Spring Festival, with opportunities for low-cost positioning [27]

格隆汇12月28日丨金城医药（维权）(300233.SZ)公布，根据税务部门对金城金素及榄都药业2017年和 2018年纳税情况的检查，金城金素及榄都药业应补缴税款及滞纳金共计2,159.68万元。截至本公告披露 日，金城金素及榄都药业的税款及滞纳金已缴纳完毕。本次补缴不涉及行政处罚。 ...

根据 2019 年《山东金城医药集团股份有限公司与傅苗青、周白水之股权转 让协议》（以下简称《股权转让协议》）第 9.19 条约定："除已向甲方披露的 情况外，目标公司及金城金素遵守有关税务法律法规规定，依法缴纳税款，如在 股权交割日之前有欠缴而被税务机关追缴和处罚的，则由乙方向目标公司及金城 金素承担被追缴部分的金额、滞纳金和罚款等所有损失。" 具体详见公司 2019 年 6 月 4 日在巨潮资讯网披露的《股权转让协议》。 山东金城医药集团股份有限公司 关于子公司补缴税款的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）控股子公司广东金城 金素制药有限公司（以下简称"金城金素"）及其全资子公司广东榄都药业有限 公司（以下简称"榄都药业"）近期分别收到国家税务总局中山市税务局下发的 《税务处理决定书》（中山税一稽处[2025]93 号、[2025]114 号），现将有关情 况公告如下： 一、基本情况 根据税务部门对金城金素及榄都药业 2017 年和 2018 年纳税情况的检查，金 城金素及榄都药业应补缴税款 ...

智通财经APP讯，金城医药(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司("金城金素") 及其全资子公司广东榄都药业有限公司("榄都药业")近期分别收到国家税务总局中山市税务局下发的 《税务处理决定书》。根据税务部门对金城金素及榄都药业2017年和2018年纳税情况的检查，金城金素 及榄都药业应补缴税款及滞纳金共计2159.68万元。截至本公告披露日，金城金素及榄都药业的税款及 滞纳金已缴纳完毕。 ...

智通财经APP讯，金城医药(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司("金城金素") 及其全资子公司广东榄都药业有限公司("榄都药业")近期分别收到国家税务总局中山市税务局下发的 《税务处理决定书》。根据税务部门对金城金素及榄都药业2017年和2018年纳税情况的检查，金城金素 及榄都药业应补缴税款及滞纳金共计2159.68万元。截至本公告披露日，金城金素及榄都药业的税款及 滞纳金已缴纳完毕。 ...

金城医药公告，控股子公司广东金城金素制药有限公司及其全资子公司广东榄都药业有限公司收到国家 税务总局中山市税务局下发的《税务处理决定书》，根据税务部门对金城金素及榄都药业2017年和2018 年纳税情况的检查，金城金素及榄都药业应补缴税款及滞纳金共计2159.68万元。截至本公告披露日， 金城金素及榄都药业的税款及滞纳金已缴纳完毕。本次补缴不涉及行政处罚。 ...

证券日报网讯12月26日，金城医药（300233）发布公告称，公司补选副董事长李家全先生为第六届董事 会董事长。 ...

（文章来源：证券日报） 证券日报网讯 12月26日，金城医药发布公告称，金城医药第六届董事会第十九次会议审议通过《关于 聘任公司高级管理人员及董事会秘书的议案》等。 ...